When will cabozantinib be launched in China?

Cabozantinib (Cabozantinib) is a targeted therapy drug that is not currently available in mainland China. Although cabozantinib has been approved for marketing in other countries and used to treat many types of cancer, its launch time in mainland China has not yet been determined. Generally, drugs need to go through the approval process of the National Medical Products Administration (NMPA) before being marketed in mainland China, including review of clinical trial data and approval of drug registration. Due to the complexity and timing uncertainty of the approval process, cabozantinib's time to market may be affected. Therefore, patients and doctors need to pay close attention to relevant drug registration and marketing developments to obtain the latest information and treatment options.